Barclays lowered the firm’s price target on Zoetis to $230 from $260 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst expects the Q1 reports to provide continuing evidence of improvement in generics and biosimilars for the specialty pharmaceuticals group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Scout Clean Energy announces 12-year VPPA with Zoetis
- MOO ETF: Agriculture Stocks Are Inexpensive and Defensive
- Heidi C. Chen to Depart, Roxanne Lagano Steps In at Zoetis
- Zoetis price target lowered to $195 from $220 at Piper Sandler
- WSJ Zoetis article does not bring new information, says William Blair
